Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

NCT07701681 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

ESCC
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
GC/GEJC

Interventions

DRUG: Sacituzumab Tirumotecan + Tagitanlimab

Sponsor

Sun Yat-sen University